Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) specializes in developing oncology and dermatology therapies. PV-10, the company’s novel investigational drug for cancer, is designed for injection into solid tumors, thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. For more information, visit the company’s website at www.pvct.com